- Global Pharma News & Resources

The Corporate Reputation of Pharma, 2017: The Patient Perspective - Asia Edition -

The "The Corporate Reputation of Pharma, 2017 - The Patient Perspective - Asia Edition" report has been added to's offering.

Introducing the results of the 2017 (2nd) edition of The Corporate Reputation of Pharma - from the Perspective of Asian Patient Groups. In total, 101 Asian patient groups from across the region participated in the 2017 survey (with 35% of the respondents being based in Australasia).

Asian patient groups (and the patients they represent), on the whole, take a more positive view of the pharmaceutical industry than patient groups from elsewhere in the world. As many as 51% of the respondent Asian patient groups stated that the pharmaceutical industry as a whole had an Excellent or Good corporate reputation in 2017 (on a par with the 50% of Asian patient groups saying the same in 2016). The equivalent figure from patient groups worldwide in 2017 was 43%.

Companies Featured

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Boehringer,ngelheim
  • Bristol-Myers Squibb
  • Eisai
  • Eli Lilly (Lilly)
  • GSK
  • Gilead Sciences
  • Janssen
  • Merck & Co/MSD
  • Novartis
  • Otsuka
  • Pfizer
  • Roche
  • Sanofi
  • Takeda

Key Topics Covered

  1. Executive Summary
  2. The Relationships that Asian Patient Groups have with Pharma, 2017
  3. Industry-Wide Findings from Asian Patient Groups, 2017
  4. Rankings of the 18 Pharma Companies, 2017 v. 2016 among Asian Patient Groups Familiar with the Companies
  5. Positionings of 11 Pharma Companies, 2017 v. 2016 among Asian Patient Groups that Work/Partner with the Companies
  6. Profiles of the 18 Companies, 2017

For more information about this report visit

View source version on

Editor Details

Last Updated: 13-Nov-2018